Literature DB >> 28585700

Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis.

Saki Hayashida1,2, Sakiko Soutome3, Souichi Yanamoto2, Shigeyuki Fujita1, Takumi Hasegawa4, Takahide Komori4, Yuka Kojima5, Hironori Miyamoto6, Yasuyuki Shibuya6, Nobuhiro Ueda7, Tadaaki Kirita7, Hirokazu Nakahara8, Mitsuyo Shinohara9, Masahiro Umeda2,3.   

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is an adverse event that may inhibit the treatment of primary disease and remarkably influence the patient's quality of life. The treatment methods for MRONJ, nonsurgical and surgical, are controversial, with no agreement as to which method provides the best outcome and should therefore be recommended. This multicenter retrospective study aimed to investigate the treatment methods and outcome in a large number of patients with MRONJ in Japan, utilizing propensity score matching analysis. A total of 361 patients with MRONJ, at eight hospitals, were registered in this study retrospectively. Various demographic and treatment-related variables were examined and analyzed to determine their correlation with the treatment outcome. After propensity score matching for treatment methods (nonsurgical versus surgical treatment), 176 patients were analyzed by logistic regression. It was shown that those with low-dose administration of an antiresorptive agent and surgical treatment had better outcomes. Furthermore, in 159 patients who underwent surgical treatment, those who underwent extensive surgery experienced significantly better treatment outcomes than those who underwent conservative surgery. This is the first study to compare treatment methods for MRONJ using propensity score matching analysis. The results indicated that extensive surgical treatment should be performed as first-choice therapy for patients with MRONJ.
© 2017 American Society for Bone and Mineral Research. © 2017 American Society for Bone and Mineral Research.

Entities:  

Keywords:  CLINICAL TRIALS; DENTAL BIOLOGY; MEDICATION-RELATED OSTEONECROSIS OF THE JAWS (MRONJ); OSTEOPOROSIS; TUMOR-INDUCED BONE DISEASE

Mesh:

Year:  2017        PMID: 28585700     DOI: 10.1002/jbmr.3191

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  32 in total

Review 1.  A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw.

Authors:  Masaya Akashi; Junya Kusumoto; Daisuke Takeda; Takashi Shigeta; Takumi Hasegawa; Takahide Komori
Journal:  Oral Maxillofac Surg       Date:  2018-10-16

2.  Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.

Authors:  T Hasegawa; S Hayashida; E Kondo; Y Takeda; H Miyamoto; Y Kawaoka; N Ueda; E Iwata; H Nakahara; M Kobayashi; S Soutome; S I Yamada; I Tojyo; Y Kojima; M Umeda; S Fujita; H Kurita; Y Shibuya; T Kirita; T Komori
Journal:  Osteoporos Int       Date:  2018-11-07       Impact factor: 4.507

3.  Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw.

Authors:  Saki Hayashida; Souichi Yanamoto; Shigeyuki Fujita; Takumi Hasegawa; Takahide Komori; Yuka Kojima; Hironori Miyamoto; Yasuyuki Shibuya; Nobuhiro Ueda; Tadaaki Kirita; Hirokazu Nakahara; Mitsuyo Shinohara; Eiji Kondo; Hiroshi Kurita; Masahiro Umeda
Journal:  J Bone Miner Metab       Date:  2019-08-13       Impact factor: 2.626

4.  Periosteal reaction of medication-related osteonecrosis of the jaw (MRONJ): clinical significance and changes during conservative therapy.

Authors:  Sakiko Soutome; Mitsunobu Otsuru; Saki Hayashida; Souichi Yanamoto; Miho Sasaki; Yukinori Takagi; Misa Sumi; Yuka Kojima; Shunsuke Sawada; Hiroshi Iwai; Masahiro Umeda; Toshiyuki Saito
Journal:  Support Care Cancer       Date:  2021-04-21       Impact factor: 3.603

5.  Nonexposed antiresorptive agent-related osteomyelitis of the jaw: a single-center cohort study.

Authors:  Takuma Watanabe; Takeshi Yoshida; Sachi Akizuki; Shigeki Yamanaka; Kazumasa Nakao; Shizuko Fukuhara; Keita Asai; Ryuji Uozumi; Kazuhisa Bessho
Journal:  J Bone Miner Metab       Date:  2022-05-09       Impact factor: 2.626

6.  Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study.

Authors:  Masanori Nashi; Toshinori Hirai; Takuya Iwamoto; Toshihiko Takenobu
Journal:  J Bone Miner Metab       Date:  2022-09-27       Impact factor: 2.976

Review 7.  Novel Cell Therapy Using Mesenchymal Stromal Cell Sheets for Medication-Related Osteonecrosis of the Jaw.

Authors:  Nobuyuki Kaibuchi; Takanori Iwata; Yoko Kawase Koga; Toshihiro Okamoto
Journal:  Front Bioeng Biotechnol       Date:  2022-05-12

8.  Nonsurgical Management of Medication-Related Osteonecrosis of the Jaws Using Local Wound Care.

Authors:  Danny Hadaya; Akrivoula Soundia; Earl Freymiller; Tristan Grogan; David Elashoff; Sotirios Tetradis; Tara L Aghaloo
Journal:  J Oral Maxillofac Surg       Date:  2018-05-29       Impact factor: 1.895

9.  Small Extracellular Vesicles Derived from Adipose Tissue Prevent Bisphosphonate-Related Osteonecrosis of the Jaw by Promoting Angiogenesis.

Authors:  Jiao Huang; Lin Wang; Weidong Tian
Journal:  Int J Nanomedicine       Date:  2021-05-07

Review 10.  Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.

Authors:  Mampei Kawahara; Shinichiro Kuroshima; Takashi Sawase
Journal:  Int J Implant Dent       Date:  2021-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.